Breast Cancer Clinical Trials in Chicago, IL

Breast Cancer Clinical Trials in Chicago, IL

View the best 10 breast cancer medical studies in Chicago, Illinois. Access promising new therapies by applying to a Chicago-based Breast Cancer clinical trial.

Trials in Chicago, Illinois

Here are the top 10 medical studies for breast cancer in Chicago, Illinois

Image of City of Hope Medical Center in Duarte, United States.

Bazedoxifene +1 More

Selective Estrogen Receptor Modulator (SERM)

Recruiting1 awardPhase 2
This trial tests a combination of two medications, bazedoxifene and conjugated estrogens, in women at risk for breast cancer who also have menopausal hot flashes. The treatment aims to reduce these symptoms and possibly lower cancer risk. Researchers will compare changes in breast tissue and hormone levels over several months between those taking the medication and those who are not. Bazedoxifene paired with conjugated estrogens is the first combination approved by the FDA for treating menopausal symptoms.
Image of University of Alabama at Birmingham in Birmingham, United States.

Seribantumab

Monoclonal Antibodies

Recruiting1 awardPhase 2
This trial is testing a new cancer treatment for patients with solid tumors that contain a specific gene fusion.
Image of Ironwood Cancer & Research Centers in Chandler, United States.

Imlunestrant +2 More

Selective Estrogen Receptor Downregulator (SERD)

Recruiting2 awardsPhase 3
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Image of Beth Israel Deaconess Medical Center in Boston, United States.

SGN-B6A

Monoclonal Antibodies

Recruiting1 awardPhase 1
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Image of University of Illinois in Chicago, United States.

Lenvatinib +1 More

Tyrosine Kinase Inhibitor

Recruiting1 awardPhase 1
This trial involves patients with untreated triple negative breast cancer who will take a pill called Lenvatinib and receive an IV drug called Pembrolizumab. Lenvatinib helps stop the tumor from growing by cutting off its blood supply, and Pembrolizumab helps the immune system attack the cancer.
Image of Northwestern Medicine Cancer Center in Warrenville, United States.

TOL2506

Hormone Therapy

Recruiting2 awardsPhase 3
This trial tests TOL2506, a treatment that stops ovaries from working, in premenopausal women and men with hormone-sensitive breast cancer. It aims to reduce hormone levels to slow down or stop cancer growth. TOL2506 is a treatment that stops ovaries from working, similar to other ovarian suppression methods.
Image of City of Hope Comprehensive Cancer Center in Duarte, United States.

Decision Aid

Recruiting1 award22 criteria
This trial is testing web-based tools to help patients with early stage breast cancer make decisions about treatment. The goal is to learn how best to implement these tools in clinical practice.
Image of Stanford University in Palo Alto, United States.

Pembrolizumab +2 More

Monoclonal Antibodies

Recruiting1 awardPhase 1 & 2
This trial tests a new drug, BDC-1001, alone and with another drug, in patients with advanced HER2-positive cancers. BDC-1001 aims to attack cancer cells directly, and the other drug boosts the immune system to fight the cancer.
Image of University of Alabama at Birmingham Cancer Center in Birmingham, United States.

Quality-of-Life Assessment

Recruiting2 awardsPhase 3
This trial looks at how well patients stick to their medication plan when given text reminders and/or phone counseling.
Image of Research Site in Little Rock, United States.

Dato-DXd

Antibody-drug conjugate

Recruiting2 awardsPhase 3
This trial is testing a new treatment for patients with a specific type of breast cancer who still have cancer after surgery and initial treatments. The treatment uses a drug called Dato-DXd, which targets and kills cancer cells, and may also include durvalumab, which helps the immune system fight cancer. The goal is to see if this new treatment works better than current options.

Phase 3 Trials

Trials With No Placebo

View More Related Trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.